

**RECEIVED
CENTRAL FAX CENTER**

DEC 10 2004

Attorney Docket No.: 5866.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al.

Serial No.: 09/550,857

Group Art Unit: 1623

Filed: April 17, 2000

Examiner: Ward, Paul V.

For: Dry Mouldable Drug Formulation

**CERTIFICATE OF FACSIMILE TRANSMISSION
703-872-9306**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment (3 pages)
2. Notice of Appeal (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Young, Josephine, fax number (703) 872-9306.

Respectfully submitted,

Date: December 10, 2004


Csaba Attila Szakolczai
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

In re Rasmussen et al.
Application No. 09/550,857
December 10, 2004

Page 2 of 3
5866.200-US (previously NN 26)
Art Unit 1623

AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims.

LISTING OF CLAIMS

1-63. cancelled

12/23/04
Do Not
Enter
SPW

64. (previously presented) A solid needle-shaped pharmaceutical composition comprising a binder that forms an amorphous matrix, at least one therapeutic agent, and, optionally, at least one non-crystallization agent, wherein the binder consists essentially of maltitol and the composition is capable of penetrating cutis or mucosa by injection without dissolution or other reconstitution.

65. (previously presented) The composition of claim 64, wherein the composition comprises one or more non-crystallization agents selected from the group consisting of sorbitol, hydrogenated oligosaccharides, and combinations thereof.

66. (previously presented) A solid needle-shaped pharmaceutical composition comprising a binder that forms an amorphous matrix and at least one therapeutic agent, and, optionally, at least one non-crystallization agent, wherein the composition is primarily composed of maltitol and the composition is capable of penetrating cutis or mucosa by injection without dissolution or other reconstitution.

67. (previously presented) The composition of claim 66, wherein the composition comprises one or more non-crystallization agents selected from the group consisting of sorbitol, hydrogenated oligosaccharides, and combinations thereof.

68. cancelled